Literature DB >> 24814494

Peripartum cardiomyopathy: predictors of recovery and current state of implantable cardioverter-defibrillator use.

Jayasree Pillarisetti1, Ashok Kondur2, Anas Alani2, Madhu Reddy1, Madhuri Reddy3, James Vacek1, Carl P Weiner3, Edward Ellerbeck4, Theodore Schreiber2, Dhanunjaya Lakkireddy5.   

Abstract

OBJECTIVES: The purpose of this study was to identify the predictors of left ventricular (LV) recovery in patients with peripartum cardiomyopathy (PPCM) and to record rates of implantable cardioverter-defibrillator (ICD) use.
BACKGROUND: PPCM is a rare, life-threatening disease. The use of ICDs has not been clearly understood in this patient group. Identification of the predictors of persistent LV dysfunction can help select patients at risk for sudden cardiac death.
METHODS: A retrospective study was conducted at 2 academic centers between January 1, 1999, and December 31, 2012. Clinical and demographic variables and delivery records of patients with a diagnosis of PPCM (International Classification of Diseases, 9th Revision code 674.5) were reviewed. Improvement in LV function was noted from echocardiography reports.
RESULTS: The total sample comprised 100 patients, of whom 55% were African Americans, 39% were Caucasians, and 6% were Hispanic, with a mean age of 30 ± 6 years. Mean left ventricular ejection fraction (LVEF) at diagnosis was 28 ± 9%. Forty-two percent of patients showed improvement in LVEF over a mean duration of 33 ± 21 months. Postpartum diagnosis (hazard ratio: 3.0; p = 0.01) and Caucasian/Hispanic race (hazard ratio: 2.2; p = 0.01) were predictors of improvement in LVEF. Only 7 of the 58 patients (12%) who did not have improvement in their LVEF had an ICD implanted. There were 11 deaths, with a trend toward higher mortality in those who did not display improved LV function (15% vs. 5%; p = 0.1).
CONCLUSIONS: More than one-third of women with PPCM improve LV function with delayed recovery noted in the majority of these patients. Caucasians and those diagnosed in the postpartum period appear to be the most likely to recover. The rate of ICD implantation for primary prevention of sudden cardiac death in this patient group is low.
Copyright © 2014 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cardiomyopathy; implantable cardioverter-defibrillator; peripartum

Mesh:

Year:  2014        PMID: 24814494     DOI: 10.1016/j.jacc.2014.04.014

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  15 in total

1.  Clinical Outcomes for Peripartum Cardiomyopathy in North America: Results of the IPAC Study (Investigations of Pregnancy-Associated Cardiomyopathy).

Authors:  Dennis M McNamara; Uri Elkayam; Rami Alharethi; Julie Damp; Eileen Hsich; Gregory Ewald; Kalgi Modi; Jeffrey D Alexis; Gautam V Ramani; Marc J Semigran; Jennifer Haythe; David W Markham; Josef Marek; John Gorcsan; Wen-Chi Wu; Yan Lin; Indrani Halder; Jessica Pisarcik; Leslie T Cooper; James D Fett
Journal:  J Am Coll Cardiol       Date:  2015-08-25       Impact factor: 24.094

Review 2.  Peripartum Cardiomyopathy: a Review for the Clinician.

Authors:  Abigail Khan; Emmanuelle Paré; Shimoli Shah
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-09-29

Review 3.  Detection and management of arrhythmias in peripartum cardiomyopathy.

Authors:  Julian Hoevelmann; Lina Hähnle; Julia Hähnle; Karen Sliwa; Charle Viljoen
Journal:  Cardiovasc Diagn Ther       Date:  2020-04

Review 4.  Molecular mechanisms of peripartum cardiomyopathy: A vascular/hormonal hypothesis.

Authors:  Natalie A Bello; Zoltan Arany
Journal:  Trends Cardiovasc Med       Date:  2015-01-15       Impact factor: 6.677

5.  Racial and Ethnic Disparities in the Trends and Outcomes of Cardiogenic Shock Complicating Peripartum Cardiomyopathy.

Authors:  Titilope Olanipekun; Temidayo Abe; Valery Effoe; Obiora Egbuche; Paul Mather; Melvin Echols; Demilade Adedinsewo
Journal:  JAMA Netw Open       Date:  2022-07-01

Review 6.  Peripartum cardiomyopathy.

Authors:  Nivedita Jha; Ajay Kumar Jha
Journal:  Heart Fail Rev       Date:  2021-01-13       Impact factor: 4.214

Review 7.  Peripartum cardiomyopathy: current management and future perspectives.

Authors:  Denise Hilfiker-Kleiner; Arash Haghikia; Justus Nonhoff; Johann Bauersachs
Journal:  Eur Heart J       Date:  2015-01-29       Impact factor: 29.983

8.  Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study.

Authors:  Denise Hilfiker-Kleiner; Arash Haghikia; Dominik Berliner; Jens Vogel-Claussen; Johannes Schwab; Annegret Franke; Marziel Schwarzkopf; Philipp Ehlermann; Roman Pfister; Guido Michels; Ralf Westenfeld; Verena Stangl; Ingrid Kindermann; Uwe Kühl; Christiane E Angermann; Axel Schlitt; Dieter Fischer; Edith Podewski; Michael Böhm; Karen Sliwa; Johann Bauersachs
Journal:  Eur Heart J       Date:  2017-09-14       Impact factor: 29.983

9.  Comparison of clinical outcomes in peripartum cardiomyopathy and age-matched dilated cardiomyopathy: A 15-year nationwide population-based study in Asia.

Authors:  Cheng-Hui Lu; Wen-Chen Lee; Michael Wu; Shao-Wei Chen; Jih-Kai Yeh; Chun-Wen Cheng; Katie Pei-Hsuan Wu; Ming-Shien Wen; Tien-Hsing Chen; Victor Chien-Chia Wu
Journal:  Medicine (Baltimore)       Date:  2017-05       Impact factor: 1.889

10.  Clinical Profi le and Predictors of Outcomes of Patients with Peripartum Cardiomyopathy: The Philippine Heart Center Experience.

Authors:  Lucky R Cuenza; Normita Manapat; Jundelle Romulo K Jalique
Journal:  ASEAN Heart J       Date:  2016-11-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.